重组人生长激素治疗青春期前ISS对于患儿临床指标的影响

The effect of recombinant human growth hormone on osteocalcin and growth rate in children with pre pubertal idiopathic short stature

目的探讨重组人生长激素(recombinant human growth hormone,rhGH)对于青春期前特发性矮身材(idiopathic short stature,ISS)患儿相关临床指标的影响。方法回顾性选取2020年1月至2022年6月在惠州市第三人民医院收治的青春期前ISS患儿纳入本次研究,将其中采取常规治疗的47例患儿纳入常规组,其中在常规治疗的基础上应用rhGH治疗的49例患儿纳入观察组。对比两组患儿治疗前及治疗后的生长指标、骨代谢指标及血清相关指标。结果治疗后,观察组患儿身高与生长速率均高于常规组(P<0.05);观察组患儿骨钙素、甲状旁腺素均高于常规组(P<0.05);观察组患儿胰岛素样生长因子结合蛋白-3(insulin-like growth factor binding protein-3,IGFBP-3)、骨碱性磷酸酶(bone alkaline phosphatase,BAP)、胰岛素样生长因子(insulin-like growth factor-1,IGF-1)均高于常规组(P<0.05)。结论重组人生长激素能够加大青春期前ISS患儿骨钙素合成量,提高患儿生长速率。

Objective To investigate the effect of recombinant human growth hormone(rhGH)on osteocalcin and growth rate in children with idiopathic short stature(ISS)before puberty.Methods Retrospective selection of pre adolescent ISS children admitted to the Huizhou Third People’s Hospital between January 2020 and June 2022 was included in this study.Among them,47 children who received routine treatment were included in the routine group,and 49 children who received rhGH treatment on the basis of routine treatment were included in the observation group.Compare the growth indicators,bone metabolism indicators,and serum related indicators of two groups of children before and after treatment.Results After treatment,the height and growth rate of the observation group were higher than those of the conventional group(P<0.05).The levels of osteocalcin and parathyroid hormone in the observation group were higher than those in the conventional group(P<0.05).The IGFBP-3,BAP,and IGF-1 levels in the observation group were higher than those in the conventional group(P<0.05).Conclusion Recombinant human growth hormone can increase the synthesis of osteocalcin and increase the growth rate in pre adolescent ISS children.